Eli Lilly and Company LLY
and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today
announced they received a positive opinion from the Committee for Medicinal
Products for Human Use (CHMP) in Europe, recommending approval of Amyvid
(Florbetapir F 18) solution for injection as a diagnostic radiopharmaceutical
indicated for Positron Emission Tomography (PET) imaging of beta-amyloid
neuritic plaque density in the brains of adult patients with cognitive
impairment who are being evaluated for Alzheimer's Disease and other causes of
cognitive impairment. Amyvid should be used in conjunction with a clinical
evaluation.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in